Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India
Background: Esophageal cancer is the fourth most common cause of cancer-related deaths in India. In 2012, the CROSS trial evaluated the benefit of induction therapy using weekly carboplatin-paclitaxel with 41.4 Gy radiation versus surgery alone. Pathological complete response (pCR) rates were 28%. O...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2018-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=272;epage=275;aulast=Bajwa |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850274355862306816 |
|---|---|
| author | Harjot Kaur Bajwa Rohith Singareddy Mahendra M Reddy Krishnam A Raju Subramanyeshwar T Rao Senthil J Rajappa |
| author_facet | Harjot Kaur Bajwa Rohith Singareddy Mahendra M Reddy Krishnam A Raju Subramanyeshwar T Rao Senthil J Rajappa |
| author_sort | Harjot Kaur Bajwa |
| collection | DOAJ |
| description | Background: Esophageal cancer is the fourth most common cause of cancer-related deaths in India. In 2012, the CROSS trial evaluated the benefit of induction therapy using weekly carboplatin-paclitaxel with 41.4 Gy radiation versus surgery alone. Pathological complete response (pCR) rates were 28%. Overall survival was improved in the combined therapy arm. However, there is limited data regarding the outcomes of preoperative chemoradiation in Indian scenario. This study was conducted to determine the response to preoperative chemoradiation at a tertiary cancer center in India. Aims: Primary objective was to evaluate the rates of pCR. Secondary objective was to determine recurrence rate and patterns of recurrence. Materials and Methods: We retrospectively reviewed patients with locally advanced esophageal cancer and gastroesophageal junction treated from September 2013 to July 2015. Patients who received preoperative radiotherapy 41.4 Gy with chemotherapy (weekly paclitaxel-carboplatin or cisplatin-5 FU or cisplatin-capecitabine) were included in this study. Chi-square test and Fischer's exact test were used for analysis. Results: Fifty patients were included in the analysis (76% – squamous cell carcinoma [SCC] and 24% – adenocarcinomas [ACC]). About 60% patients received weekly paclitaxel-carboplatin (CROSS protocol), 32% cisplatin-5 FU, and 8% cisplatin-capecitabine. pCR rate was 39.6%. pCR rate was higher in SCC versus ACC (44.7% vs. 20%) and in paclitaxel-carboplatin than cisplatin-5FU or cisplatin-capecitabine (48.3% vs. 25% vs. 33.3%). At a median follow-up of 12 months, 38 patients were alive, 8 died, and 4 lost to follow-up. Of the 10 patients that recurred, 8 were distant recurrences. Conclusion: Our study results show favorable pCR rate after preoperative CRT with significant higher rate in SCC and patients receiving CROSS regimen. Majority of the recurrences were distant recurrences. |
| format | Article |
| id | doaj-art-6ac15630c6774c6586aa2909bb23da74 |
| institution | OA Journals |
| issn | 0971-5851 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-6ac15630c6774c6586aa2909bb23da742025-08-20T01:51:10ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512018-01-0139327227510.4103/ijmpo.ijmpo_16_16Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in IndiaHarjot Kaur BajwaRohith SingareddyMahendra M ReddyKrishnam A RajuSubramanyeshwar T RaoSenthil J RajappaBackground: Esophageal cancer is the fourth most common cause of cancer-related deaths in India. In 2012, the CROSS trial evaluated the benefit of induction therapy using weekly carboplatin-paclitaxel with 41.4 Gy radiation versus surgery alone. Pathological complete response (pCR) rates were 28%. Overall survival was improved in the combined therapy arm. However, there is limited data regarding the outcomes of preoperative chemoradiation in Indian scenario. This study was conducted to determine the response to preoperative chemoradiation at a tertiary cancer center in India. Aims: Primary objective was to evaluate the rates of pCR. Secondary objective was to determine recurrence rate and patterns of recurrence. Materials and Methods: We retrospectively reviewed patients with locally advanced esophageal cancer and gastroesophageal junction treated from September 2013 to July 2015. Patients who received preoperative radiotherapy 41.4 Gy with chemotherapy (weekly paclitaxel-carboplatin or cisplatin-5 FU or cisplatin-capecitabine) were included in this study. Chi-square test and Fischer's exact test were used for analysis. Results: Fifty patients were included in the analysis (76% – squamous cell carcinoma [SCC] and 24% – adenocarcinomas [ACC]). About 60% patients received weekly paclitaxel-carboplatin (CROSS protocol), 32% cisplatin-5 FU, and 8% cisplatin-capecitabine. pCR rate was 39.6%. pCR rate was higher in SCC versus ACC (44.7% vs. 20%) and in paclitaxel-carboplatin than cisplatin-5FU or cisplatin-capecitabine (48.3% vs. 25% vs. 33.3%). At a median follow-up of 12 months, 38 patients were alive, 8 died, and 4 lost to follow-up. Of the 10 patients that recurred, 8 were distant recurrences. Conclusion: Our study results show favorable pCR rate after preoperative CRT with significant higher rate in SCC and patients receiving CROSS regimen. Majority of the recurrences were distant recurrences.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=272;epage=275;aulast=BajwaCarcinoma Esophaguspathological complete responsepreoperative chemoradiation |
| spellingShingle | Harjot Kaur Bajwa Rohith Singareddy Mahendra M Reddy Krishnam A Raju Subramanyeshwar T Rao Senthil J Rajappa Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India Indian Journal of Medical and Paediatric Oncology Carcinoma Esophagus pathological complete response preoperative chemoradiation |
| title | Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India |
| title_full | Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India |
| title_fullStr | Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India |
| title_full_unstemmed | Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India |
| title_short | Preoperative chemoradiation in carcinoma esophagus: Experience from a tertiary cancer center in India |
| title_sort | preoperative chemoradiation in carcinoma esophagus experience from a tertiary cancer center in india |
| topic | Carcinoma Esophagus pathological complete response preoperative chemoradiation |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2018;volume=39;issue=3;spage=272;epage=275;aulast=Bajwa |
| work_keys_str_mv | AT harjotkaurbajwa preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia AT rohithsingareddy preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia AT mahendramreddy preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia AT krishnamaraju preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia AT subramanyeshwartrao preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia AT senthiljrajappa preoperativechemoradiationincarcinomaesophagusexperiencefromatertiarycancercenterinindia |